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Background: Soft tissue sarcomas are a group of neoplasms with differentiation towards mesenchymal tissue, many of which are
aggressive and chemotherapy resistant. Histology and immunoprofiles often overlap with neoplasms of other lineages, and
establishing an accurate histopathological diagnosis is crucial for correct management, and therapeutic stratification. The
endosialin cell surface glycoprotein is predominantly expressed by stromal fibroblasts and pericytes in epithelial neoplasms;
however, tumour cell expression has been reported in small series of sarcomas.
Methods: We assessed endosialin expression by immunohistochemistry in a large set of 514 human soft tissue sarcomas.
Results: Tumour cell endosialin expression was seen in 89% of undifferentiated pleomorphic sarcomas (104/117), 77% adult
fibrosarcomas/spindle cell sarcomas (20/26), 62% synovial sarcomas (37/60), 51% leiomyosarcomas (94/185) and 31% rhabdomyo-
sarcomas (39/126).
Conclusions: Endosialin immunohistochemistry has potential to distinguish undifferentiated and poorly differentiated sarcomas
from other poorly differentiated, non-mesenchymal neoplasms. A Phase II trial randomising patients with advanced sarcomas to
receive chemotherapy with/without an endosialin therapeutic antibody has recently completed enrolment. Endosialin expression
could be used to select patients for such clinical trials. Based on our results, patients with undifferentiated pleomorphic sarcoma
may be particularly suitable for such a therapeutic approach.
Soft tissue sarcomas are a complex group of childhood and adult
neoplasms with differentiation towards mesenchymal tissue, which
can arise almost anywhere in the body. While traditionally
classified according to the mature mesenchymal tissue they most
resemble, many subtypes are of uncertain differentiation with no
normal cellular counterpart. As they present with similar clinical
and radiologic findings, correct histopathological diagnosis is
crucial, and morphology with ancillary immunohistochemistry
remains the diagnostic cornerstone. This can be difficult in
sarcomas lacking specific immunohistochemical differentiation
and which overlap morphologically both with other sarcoma
subtypes and with poorly differentiated non-mesenchymal neo-
plasms. Furthermore, many sarcomas behave aggressively, and
surgery with or without radiation remains the mainstay of
management for localised disease, as most, with the exception of
select subgroups such as small round cell tumours, are resistant to
conventional chemotherapy. As many sarcomas occur in sites
where adequate surgical clearance is not possible, and the
prognosis is generally poor for recurrent and metastatic disease,
the need for novel rationally selected therapies is urgent.
The discovery of more specific ancillary diagnostic immunohisto-
chemical markers might aid the distinction of sarcomas from
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non-mesenchymal mimics, and enable better sub-classification into
groups that will respond to specific targeted therapies.
Interest in endosialin (CD248) stemmed from the demonstra-
tion that it was the most highly upregulated transcript in colorectal
cancer tumour vasculature, compared to the vasculature of normal
adjacent tissue. This led to it being designated as ‘tumour
endothelial marker 1’ (St Croix et al, 2000). However, examination
of a range of human cancers, although confirming this stromal
upregulation of endosialin, has demonstrated that its expression is
confined to stromal fibroblasts and pericytes of tumour vasculature
rather than endothelium (MacFadyen et al, 2007; Rouleau et al,
2008; Simonavicius et al, 2008). Its expression and biologic role in
sarcomas is little known. However, in comparison to other solid
tumours, endosialin expression as detected by immunohistochem-
istry or mRNA analysis (Dolznig et al, 2005; Rouleau et al, 2008;
O’Shannessy et al, 2016) has been reported in the tumour cell
compartment in relatively small series of sarcomas. In view of this,
the aim of this study was to assess the expression of endosialin in a
large tissue microarray (TMA) of 514 human soft tissue sarcomas
by immunohistochemistry. A second aim of this study was to
obtain further data regarding endosialin expression in various
sarcoma subtypes and stromal elements, in order to provide
information for ongoing clinical trials of anti-endosialin agents.
MATERIALS AND METHODS
All TMAs had multiple cores from each patient sample. The two
rhabdomyosarcoma (RMS) TMAs comprised material (of both
embryonal (ERMS) and alveolar (ARMS) subtypes) from clinical
biopsies of patients (through the Children’s Cancer and Leukemia
Group, United Kingdom (Local Research Ethics Committee
(LREC) protocol No. CCR-1836; Multi-Regional Research Ethics
Committee/98/4/023 with consent where required) and Kiel
Paediatric Tumour Registry, Department of Paediatric Pathology,
University of Kiel, Germany respectively (Wachtel et al, 2006).
The adult soft tissue sarcoma TMAs were constructed as
previously described (Kononen et al, 1998), and comprised cores
from tumour biopsies of patients with synovial sarcoma, adult
fibrosarcoma/spindle cell sarcoma not otherwise specified (i.e. for
which all specific morphologic and genetic subtypes had been
excluded), leiomyosarcoma and undifferentiated pleomorphic
sarcoma (UPS) with appropriate approval for study (CCR-2015).
Tumour diagnoses had been previously confirmed by a specialist
soft tissue pathologist (CF). Synovial sarcomas comprised mono-
phasic spindle cell neoplasms or biphasic spindle cell and
epithelioid neoplasms with immunoprofiles and genetics as
previously described (Thway and Fisher, 2014). Leiomyosarcomas
comprised neoplasms with the appropriate morphology of
intersecting fascicles of cells often with blunt-ended nuclei which
expressed two or all of the muscle markers desmin, smooth muscle
actin and h-caldesmon (typically uniformly but at least focally),
and did not express markers of other lineages such as of skeletal
muscle differentiation. Rhabdomyosarcomas all showed desmin
expression, as well as nuclear expression of markers of skeletal
muscle differentiation myogenin and MyoD1. The category ‘UPS’
comprised morphologically pleomorphic soft tissue mesenchymal
neoplasms in which no specific line of differentiation was
identifiable morphologically or immunohistochemically. Tumours
were only placed in this category when all possible lineages had
been excluded (including dedifferentiated types of specific soft
tissue sarcoma such as liposarcoma) (Fletcher et al, 2013).
Four-micrometre TMA sections were cut onto glass slides,
dewaxed in xylene, then rehydrated through a series of ethanols
into water. For antigen-retrieval slides were then pressure cooked
for 2min in 0.01M pH 6.0 citrate target retrieval buffer, washed
5min under running water and stained with the anti-endosialin
monoclonal antibody B1/35.1 (MacFadyen et al, 2005), 1mg ml 1
at a 1 : 500 dilution for 1 h at room temperature. Detection was
achieved with the Vectastain avidin-biotin complex system
according to the manufacturer’s protocol (Vector Laboratories,
Burlingame, CA, USA). Finally slides were dehydrated through a
series of alcohols, cleared in xylene and mounted in 1,3-diethyl-8-
phenylxanthine. Sections of normal human breast plus cores of
normal human placenta within the TMAs served as positive
immunohistochemical controls. Cores of liver and skeletal muscle
served as negative controls.
Each core was first scored for staining intensity (absent, weak,
moderate or strong) by a pathologist (KT), blinded to patient
disease and outcome. Only well-defined, moderate or strong cell
membranous and/or cytoplasmic staining was considered positive
for this study, and ill-defined, nuclear or perinuclear staining was
disregarded. Scoring was then performed both for tumour cells of
each sarcoma and, when present in the cores, for tumour-
associated stromal fibroblasts and pericytes. Immunoreactivity as
shown in Table 1 was semiquantitatively evaluated as negative
(i.e. 0% of cells stained), þ 1 (focally positive, 1–10% cells), þ 2
(positive in 11–50% of cells) or þ 3 (positive in 450% cells).
Following scoring, TMA slides were scanned using a Hama-
matsu NanoZoomer-XR C12000, viewed in NDP.view2 and
selected images exported into Adobe Photoshop CS6.
For confocal imaging, sections were subject to antigen retrieval
as described above and then stained with anti-endosialin antibody
B1/35.1 (2 mg ml 1) and anti-endomucin antibody (Abcam
ab45771 (2 mg ml 1) or anti-a-smooth muscle actin (aSMA)
antibody (Sigma-Aldrich, Dorset, UK; clone: 1A4, 0.4 mg ml 1),
followed by AlexaFluor conjugated secondary antibodies (Mole-
cular Probes, Eugene, OR, USA) as previously described
(Simonavicius et al, 2008). Nuclei were counterstained with
14 nM DAPI (Molecular Probes), slides were rinsed in PBS and
mounted with Vectashield (Vector Laboratories). Fluorescent
images were collected sequentially in three channels on a Leica
Microsystems TCS-SP2 confocal microscope. All images were
taken at the same settings and exported from the Leica software
into Adobe Photoshop CS6.
RESULTS
Tumour specimens from 514 patients were examined, and the
findings for each sarcoma, summarised in Table 1, are described
below:
Controls. Figure 1 with higher power images shown in
Supplementary Figure S1. Adult non-neoplastic human breast
(positive control) showed, as previously reported (Simonavicius
et al, 2008), strong endosialin expression on the stromal fibroblasts
surrounding the terminal duct lobular units (Figure 1A). Normal
human placenta (positive control) showed strong endosialin
staining on the stromal cells within the placental villi surrounded
by the endosialin-negative syncytiotrophoblastic cells (Figure 1B).
Normal adult human skeletal muscle (Figure 1C) and liver
(Figure 1D) control cores within TMAs were negative throughout.
Undifferentiated pleomorphic sarcoma. Total of 117 patients
(Figure 2A–H; higher power images shown in Supplementary
Figure S2). Of the 104 UPS samples analysed, 104 (89%) had
endosialin expression in tumour cells (Figure 2B–E; see Table 1 for
full details). In addition, 94 (80%) displayed endosialin-positive
stromal fibroblasts (see Figure 2E), and all 25 patients whose
samples had detectable vasculature had endosialin-positive peri-
cytes (see Figure 2F). To confirm expression of endosialin on
stromal cells, UPS sections were co-stained for endosialin and
either endomucin, as a marker of endothelial cells, or a-smooth
muscle actin, as a marker of activated cancer-associated fibroblasts.
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As illustrated in Figure 2G, endosialin expression on the
vasculature was restricted to pericytes, identified by their close
apposition to endomucin-positive endothelial cells. As illustrated
in Figure 2H, endosialin expression in the stromal bed was
colocalised with a-smooth muscle actin-positive fibroblasts.
Rhabdomyosarcoma. Total of 126 patients (Figure 3A–D; higher
power images shown in Supplementary Figure S3A–D) comprising
100 embryonal rhabdomyosarcoma and 26 alveolar rhabdomyo-
sarcoma, of which 35 (35%) (Figure 3A–C) and 4 (15%)
(Figure 3D), respectively, contained endosialin expression in
the tumour cells and 71 (71%) embryonal rhabdomyosarcoma
and 12 (46%) alveolar rhabdomyosarcoma showed endosialin
expression in stromal fibroblasts. Where the vasculature was
evaluable (19 cases), all of the embryonal rhabdomyosarcoma and
alveolar rhabdomyosarcoma tumours showed endosialin-positive
pericytes.
Synovial sarcoma. Total of 60 patients, of which 37 (62%) had
endosialin expression in neoplastic cells (Figure 3E and F;
Supplementary Figure S3E and F) and 46 (77%) showed expression
in stromal fibroblasts (Figure 3F). Where the vasculature was
evaluable (28 tumours), 100% had endosialin-positive pericytes
associated with the vasculature.
Adult fibrosarcoma/spindle cell sarcoma not otherwise specified.
Total of 26 patients of which 20 (77%) had tumours expressing
endosialin in tumour cells, 19 (73%) displayed expression of
endosialin on stromal fibroblasts and all 5 tumours with evaluable
vasculature had endosialin-positive pericytes.
Leiomyosarcoma. Total of 185 patients (Figure 3G and H;
Supplementary Figure 3G and H), of which 94 (51%) displayed
endosialin expression in tumour cells, 107 (58%) had endosialin-
positive stromal fibroblasts and 60/61 (98%) patients who had
samples with detectable vasculature had endosialin-positive pericytes.
Table 1. Immunohistochemical expression of endosialin in soft tissue sarcoma tissue microarrays
Tumour cell expression
Stromal fibroblast
expression
Pericyte expression
Sarcoma type
No. of
patients þ1 þ2 þ3 Total positive þ1 þ2 þ3 Total positive þ1 þ2 þ3 Total positive
Undifferentiated pleomorphic sarcoma
(UPS)
117 8 21 75 104/117 (88.9%) 11 16 67 94/117 (80.3%) 2/25 11/25 12/25 25/25 (100%)
Embryonal rhabdomyosarcoma (ERMS) 100 13 14 8 35/100 (35.0%) 25 25 21 71/100 (71.0%) 6/78 29/78 43/78 78/78 (100%)
Alveolar rhabdomyosarcoma (ARMS) 26 2 1 1 4/26 (15.4%) 4 3 5 12/26 (46.2%) 2/19 2/19 15/19 19/19 (100%)
Synovial sarcoma 60 14 14 9 37/60 (61.7%) 12 20 14 46/60 (76.7%) 2/28 13/28 13/28 28/28 (100%)
Adult fibrosarcoma/spindle cell sarcoma of
no special type
26 6 8 6 20/26 (76.9%) 2 9 8 19/26 (73.1%) 0/5 3/5 2/5 5/5 (100%)
Leiomyosarcoma 185 16 31 47 94/185 (50.8%) 22 37 48 107/185 (57.8%) 7/61 26/61 27/61 60/61 (98.4%)
A B
DC
Figure 1. Endosialin expression in control human tissues. (A) Normal adult breast tissue shows strong endosialin expression on the stromal
fibroblasts (black arrows) surrounding the endosialin-negative luminal and myoepithelial cells within the terminal duct lobular units (red
arrowheads). (B) Placental tissue shows strong endosialin expression within the placental villi (black arrows), with absence of expression within the
syncytiotrophoblastic cells (red arrowheads). (C, D) Normal skeletal muscle and liver tissue, respectively, show no endosialin expression. Scale bar,
100mm. See Supplementary Figure S1 for higher power images.
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Figure 2. Endosialin expression in undifferentiated pleomorphic sarcoma (UPS). (A) Haematoxylin and eosin-stained section shows markedly
pleomorphic, cellular tumour composed of sheets of spindle cells (black arrowheads) interspersed with ovoid cells (white arrowheads).
(B, C) Examples 1 and 2. Both these UPS specimens show strong endosialin positivity, which is uniform throughout the tumour cells in panel B, but has
a more focal, heterogeneous tumour cell distribution in panel C. (D) Example 3. UPS showing strong but focal membranous expression of endosialin
(black arrowheads) on approximately 40% of tumour cells interspersed with endosialin-negative tumour cell (red arrowheads). (E) Example 4.
The neoplastic cells (top left of field) show focal endosialin expression (black arrowheads), but endosialin expression is stronger within the surrounding
stroma (black arrows). (F) Example 5. UPS with endosialin-negative tumour cells (red arrowheads), but endosialin is strongly expressed by the pericytes
(black arrows). (G, H) Confocal microscopy of UPS specimens with stromal endosialin expression but no tumour cell positivity. Panel G, illustrating
tumour vasculature with endosialin-positive pericytes (arrows) closely apposed to endomucin-positive endothelial cells (arrowheads). Panel H
illustrating co-localisation of endosialin and a-smooth muscle actin in stromal fibroblasts (arrowheads). Scale bars, 100 mm (panels A–F), 50mm
(panels G, H). See Supplementary Figure S2 for higher power images.
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DISCUSSION
This study confirms that endosialin is expressed not only in
pericytes and stromal fibroblasts of a range of human soft tissue
sarcomas, but also in the neoplastic sarcoma cells. This is in
contrast to the perivascular and fibroblastic distribution of
endosialin expression previously reported in carcinomas and
neoplasms of other lineages. Expression was seen in the neoplastic
cells of 89% (n¼ 104/117) of UPS, 77% of adult fibrosarcomas/
spindle cell sarcomas (20/26), 62% of synovial sarcomas (37/60),
51% of leiomyosarcomas (94/185) and 31% of RMS (39/126).
A B
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Figure 3. Endosialin in expression in non-UPS sarcomas. (A, C) Embryonal rhabdomyosarcoma. Panel A, Example 1 showing strong uniform
expression of endosialin throughout the ovoid and spindle tumour cell populations. Panel B, Example 2 where the spindle and ovoid cells of the
neoplasm show no expression of endosialin (red arrowheads), but strong endosialin expression on the pericytes of the tumour vasculature (black
arrows). Panel C, Example 3–as in example 2 except additional expression of endosialin on stromal fibroblasts (black arrows). (D) Alveolar
rhabdomyosarcoma showing focal expression of endosialin (black arrowheads) throughout the ovoid and spindle cell population, interspersed by
endosialin-negative tumour cells (red arrowheads). Characteristic fibrous septa containing endosialin-positive fibroblasts (black arrows) divide the
nests of round cells. (E, F) Biphasic synovial sarcoma. Panel E, haematoxylin and eosin-stained section showing spindle cell (black arrowheads) and
glandular (white arrowheads) tumour cell components. Panel F illustrates an example with strong endosialin expression within the spindle cell
component (black arrowheads), whereas the glandular component, composed of more rounded tumour cells, is largely endosialin-negative (red
arrowheads). (G, H) Leiomyosarcoma. Panel G illustrates a tumour with high-level endosialin expression throughout. Panel H illustrates a tumour
with focal endosialin expression. Scale bar, 100 mm. See Supplementary Figure S3 for higher power images.
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Endosialin is a transmembrane glycoprotein encoded by the
CD248 gene in humans, and belonging to a family of C-type lectin
transmembrane receptors. Its precise function remains to be
understood, but it is associated with a role in angiogenesis during
embryonic development, as well as postnatally in tumour
development and growth and some inflammatory lesions (Rupp
et al, 2006; Simonavicius et al, 2012). Endosialin is expressed by
fibroblasts and pericytes in the embryo, and is downregulated
during development, resulting in significant loss of expression in
adult tissues (MacFadyen et al, 2007; Huang et al, 2011). In
epithelial neoplasias, expression of endosialin is typically detected
on stromal fibroblasts and tumour vessel-associated pericytes
(MacFadyen et al, 2005; Rupp et al, 2006; MacFadyen et al, 2007;
Bagley et al, 2008; Christian et al, 2008; Simonavicius et al, 2008)
but not in the tumour cell compartment or endothelium
(MacFadyen et al, 2005; Bagley et al, 2008; Christian et al, 2008;
Simonavicius et al, 2008). This upregulated stromal expression of
endosialin has been reported in a wide range of human cancers,
including breast carcinomas (Rouleau et al, 2008), ovarian
epithelial, colonic and rectal carcinomas (Bagley et al, 2008), small
cell lung cancer, neuroblastoma and melanoma (Rouleau et al,
2011), metastatic melanomas and squamous cell carcinomas
(Huber et al, 2006), high grade gliomas/glioblastoma multiforme,
anaplastic astrocytomas and metastatic carcinomas to brain (Brady
et al, 2004; Simonavicius et al, 2008). While its function in these
stromal cells is yet to be clearly defined, knockout mouse models
have shown the absence of endosialin expression results in reduced
growth, invasion and metastasis of human tumour xenografts
(Nanda et al, 2006; Tomkowicz et al, 2007), with increase in small
immature vessels and decrease in medium and large tumour
vessels, suggesting a role in controlling the interaction between
tumour cells, endothelia and the extracellular matrix.
In contrast to the majority of human tumours of epithelial
origin where endosialin expression is not detected on the tumour
cells, tumour cell endosialin expression has been reported in a
subset of neuroblastomas (Rouleau et al, 2011) and sarcomas.
Regarding the latter, Rouleau et al assessed the immunohisto-
chemical expression of endosialin on 86 formalin-fixed, paraffin-
embedded human clinical sarcoma specimens (Rouleau et al,
2008), and documented expression in different cell types; 51%
(54/86) showed endosialin expression in malignant cells, 78%
(67/86) in vasculature and 22% (19/86) in stromal cells. Endosialin
expression was also found in 22/42 human sarcoma cell lines
screened in vitro, with a positive correlation between mRNA and
protein levels. When implanted in vivo, expression was seen at all
sites of tumour dissemination. Recent studies by this group on
endosialin-positive sarcoma cell lines have shown maintenance of
endosialin expression in sarcoma side population cells with stem-
cell like properties, reinforcing the hypothesis that endosialin is a
potential therapeutic target in sarcoma (Rouleau et al, 2012; Sun
et al, 2015).
Using a larger sample of human clinical tumour specimens from
514 patients, we have demonstrated endosialin expression in some
of the most common sarcoma subtypes. Consistent with our data,
Rouleau et al (2008) reported endosialin protein expression in
sarcoma cells in 80% (8/10) of synovial sarcomas, 75% (6/8) of
fibrosarcomas, 73% (8/11) of UPS and 10% (1/10) of RMS, with
similar results obtained in an independent series (O’Shannessy
et al, 2016). The high expression of endosialin shown in soft tissue
sarcomas (rather than only in tumour stroma and pericytes)
suggests it might have potential diagnostic utility in discriminating
sarcomas from other neoplasms. A significant diagnostic hurdle in
soft tissue pathology is the lack of a reliable immunohistochemical
marker of mesenchymal lineage. While vimentin, a type III
intermediate filament protein forming the major cytoskeletal
component of mesenchymal cells, is commonly used in diagnostic
immunohistochemical panels, it is also expressed extensively in
neoplasms of other lineages, making it an ineffective diagnostic
marker.
The high expression of endosialin seen in UPS in our study
suggests that its expression might be upregulated in sarcomas as a
consequence of its undifferentiated phenotype. Endosialin expres-
sion was also present in almost 80% of fibrosarcomas/ spindle cell
sarcomas not otherwise specified in this study; these are a group of
spindle cell neoplasms with fascicular or ‘herringbone’ architecture
and which also lack a specific immunophenotype, again supporting
the possibility that endosialin might be an indicator of
both ‘mesenchymal’ differentiation and lack of differentiation.
Endosialin is expressed in a smaller proportion of synovial
sarcomas, leiomyosarcomas and RMS, which are each indisputably
better differentiated, having distinct morphologic patterns and
immunoprofiles.
In sarcomas endosialin is expressed in both neoplastic
cells and those of tumour stroma, as demonstrated by our
co-immunofluorescent staining. This could have importance in the
interaction between tumour cells, tumour fibroblasts and pericytes
leading to neoplastic progression and dissemination. Ontuxizumab
(MORAb-004) is a humanised monoclonal antibody targeting
endosialin, and has shown preliminary anti-tumour activity in a
Phase I trial in treatment-refractory solid tumours, including
sarcoma patients (Diaz et al, 2015). Our results are relevant, as a
randomised Phase II trial of ontuxizumab has recently completed
enrolment. Patients with advanced soft tissue sarcoma were
randomised to receive gemcitabine/ docetaxel with the antibody
or with placebo. Patients were stratified into four groups:
liposarcoma, UPS, leiomyosarcoma and a heterogeneous group
of other subtypes. Consequently, further data on endosialin
expression in individual subtypes, particularly UPS, are very
important and may guide further evaluation of this antibody.
While further work is required in assessing endosialin
expression in other sarcoma types, particularly to further explore
the differential expression of endosialin on differentiated vs less
differentiated sarcomas, this study suggests that endosialin may
be of potential use as an ancillary diagnostic aid in three ways: first,
as a putative marker of ‘mesenchymal’ lineage, second in
discriminating pleomorphic sarcomas from poorly differentiated
non-mesenchymal neoplasms and finally as a potential marker of
the progressive ‘undifferentiation’ of mesenchymal tumours.
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Supplementary Figure S1. Endosialin expression in control human tissues. 
 
Higher power images of panels shown in Figure 1. (A) Placenta. Black arrowheads 
endosialin-positive stromal cells within the placental villi. Red arrowheads, 
endosialin-negative syncytiotrophoblastic cells. (B) Normal adult breast. Black 
arrowheads, endosialin-positive stromal fibroblasts. Red arrowheads, endosialin-
negative luminal and myoepithelial cells. (C) Skeletal muscle, (D) Liver. Scale bar, 50 
µm.  
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Figure 2. Endosialin expression in undifferentiated pleomorphic sarcoma 
(UPS). 
Higher power images of panels shown in Figure 2. (A) Haematoxylin and eosin 
stained UPS section illustrating sheets of spindle tumour cells (black arrowhead) 
interspersed with ovoid tumour cells (white arrowheads). (B,C) Two UPS specimens 
showing strong endosialin positivity within the tumour cells, which is uniform in panel 
B example, but more focal in panel C example. (D) UPS showing strong but focal 
tumour cell endosialin expression (black arrowheads) interspersed with endosialin-
negative tumours cells (red arrowheads). (E) Neoplastic cells (top left of field) show 
focal endosialin expression (arrowheads), but endosialin expression is stronger 
within the surrounding stroma (arrows). (F) UPS with endosialin-negative tumour 
cells (red arrowheads) but strong endosialin expression by the pericytes (arrows). 
(G,H) Examples of UPS with stromal endosialin expression but no tumour cell 
positivity. Panel G, illustrating tumour vasculature with endosialin-positive pericytes 
(arrows) closely apposed to endomucin-positive endothelial cells (arrowheads). 
Panel H illustrating co-localisation of endosialin and αSMA in stromal fibroblasts 
(arrowheads). Scale bars, 50 µm (panels A-F), 25 µm (panels G,H). 
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Figure 3. Endosialin in expression in non-UPS sarcomas 
Higher power images of panels shown in Figure 3. (A,C) Embryonal 
rhabdomyosarcoma (ERMS). (A) ERMS with strong expression of endosialin 
throughout the ovoid and spindle tumour cell populations. (B)  ERMS with endosialin-
negative tumour cells (red arrowheads), but strong endosialin expression on the 
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pericytes (arrows). (C) ERMS with endosialin-negative tumour cells (red arrowheads), 
but strong endosialin expression on the stromal fibroblasts (arrows). (D) Alveolar 
rhabdomyosarcoma (ARMS) showing focal endosialin expression within the sheets 
of round cells (black arrowheads), interspersed with endosialin-negative tumour cells 
(red arrowheads). Characteristic fibrous septa dividing the nests of round cells 
contain endosialin-positive fibroblasts (arrows). (E,F) Biphasic synovial sarcoma. 
Panel E, H&E-stained section showing spindle cell (black arrowheads) and glandular 
(white arrowheads) tumour cell components. Panel F illustrates an example with 
strong endosialin expression within the spindle cell component (black arrowheads) 
surrounded by endosialin-negative rounded cells of the glandular component (red 
arrowheads). (G,H) Leiomyosarcoma. Panel G illustrates a tumour with high-level 
endosialin expression throughout. Panel H illustrates a tumour with focal endosialin 
expression. Scale bar, 50 µm.  
